Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Chemo-Immunotherapy in Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
NCT06188676Phase 3Active, not recruiting
- Sponsor
- National Medical Research Center for Hematology
- Start
- Apr 2022
- Primary completion
- Apr 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab in primary mediastinal large B-cell lymphoma (PMBCL), sponsored by National Medical Research Center for Hematology. Started Apr 2022; status: active, not recruiting.
02
Drugs
03
Conditions
primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT06188676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06188676.